754 studies found for:    Open Studies | "Lymphoma, Non-Hodgkin"
Show Display Options
Rank Status Study
21 Recruiting Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma
Conditions: Mycoses;   Sezary Syndrome;   Lymphoma, T-Cell, Cutaneous;   Bone Marrow Transplant Failure;   Lymphoma, Non-Hodgkin;   Cutaneous T-cell Lymphoma
Interventions: Drug: anti-thymocyte globulin;   Drug: cyclosporine
22 Not yet recruiting Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: Standard anti-emetics in conjunction with R-CHOP
23 Not yet recruiting A Phase 1/2, Dose Escalation, Cohort Expansion Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors
Conditions: Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Mantle-Cell;   Lymphoma, Follicular;   Cancer;   Neoplasm;   Tumor;   Lymphoma, Malignant;   Lymphoma, B-cell;   Lymphoma, Non-Hodgkin
Interventions: Drug: ASN002 Dose Escalation;   Drug: ASN002 MTD
24 Recruiting A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.
Conditions: Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Non-Hodgkin
Interventions: Drug: Obinutuzumab;   Drug: CC-122
25 Recruiting Study of Lymphoma in Asia
Conditions: Lymphoma, Non-Hodgkin;   Multiple Myleoma;   Lympocytic, Follicular;   Leukemia;   Hodgkin Lymphoma
Intervention:
26 Recruiting Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant
Conditions: Acute Lymphoblastic Leukemia;   Leukemia Acute Myeloid;   Lymphoma, Non-Hodgkin;   Myelodysplastic Syndrome;   Immunologic Deficiency Syndromes
Intervention: Biological: BPX-501 T cells and AP1903
27 Recruiting BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: BI 836826
28 Not yet recruiting Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab—Phase I Trial in Indolent B-cell Lymphoma
Conditions: Lymphoma, Non-Hodgkin;   Lymphoma, Follicular;   Lymphoma, Mantle-Cell;   Lymphoma, Small-Cell;   Waldenstrom Macroglobulinemia;   Lymphoma, B-Cell, Marginal Zone
Interventions: Drug: Rituximab;   Drug: Bendamustine;   Drug: Vincristine sulfate liposome injection
29 Recruiting Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Cyclophosphamide;   Drug: Carmustine;   Drug: Etoposide;   Drug: Filgrastim;   Drug: Antithymocyte globulin;   Drug: Cyclosporine;   Drug: Mycophenolate mofetil;   Drug: rituximab
30 Recruiting Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma
Conditions: Hodgkin Disease;   Lymphoma, Non-Hodgkin
Interventions: Drug: Carmustine;   Drug: Etoposide phosphate;   Drug: Cytarabine;   Drug: Melphalan HCl (propylene glycol-free)
31 Recruiting Epidemiology of Burkitt Lymphoma in East Africa Children or Minors (EMBLEM)
Conditions: Lymphoma, Non-Hodgkin;   Malaria;   Herpesvirus 4, Human
Intervention:
32 Unknown  Cytogenetic Analysis of Bone Marrow Specimen Prior to High Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease
Conditions: Lymphoma, Non-Hodgkin;   Hodgkin Disease
Intervention: Procedure: Cytogenetic Analysis of Bone Marrow Specimen
33 Recruiting Family Study of Lymphoproliferative Disorders
Conditions: Lymphoma, Non-Hodgkin;   Leukemia, Lymphocytic, Chronic, B-Cell;   Lymphoma, B-Cell;   Monoclonal B-Cell Lymphocytosis;   Multiple Myeloma
Intervention:
34 Recruiting Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Lenalidomide;   Drug: Rituximab
35 Recruiting BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Rituximab;   Drug: BI 695500
36 Recruiting IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
Conditions: Lymphoma, Non-Hodgkin;   Chronic Lymphocytic Leukemia
Intervention: Drug: IMGN529
37 Unknown  Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at Diagnosis
Conditions: Lymphoma, Non-Hodgkin;   Diffuse Large B-cell Lymphoma
Intervention: Drug: Rituximab, Cytarabine
38 Recruiting Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease
Conditions: Lymphoma, Non-Hodgkin;   Hodgkin's Disease
Intervention:
39 Recruiting Tissue Collection for Studies of Lymph Cancer
Conditions: Hodgkin Disease;   Lymphoma, Non-Hodgkin;   Multiple Myeloma;   Lymphomatoid Granulomatosis;   Leukemia-Lymphoma, Adult T-Cell
Intervention:
40 Unknown  A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.
Conditions: Diffuse Large B Cell Lymphoma;   Lymphoma, Non-Hodgkin
Interventions: Drug: Doxil;   Drug: Cyclophosphamide;   Drug: Vincristine;   Drug: Prednisone;   Drug: Rituximab;   Drug: Pegfilgrastim

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years